Artificial intelligence (AI) diagnostic health care company Digital Diagnostics has announced the availability of its LumineticsCore Al diagnostic system in the southeast region of the US.
Previously known as IDx-DR, LumineticsCore is a De Novo Food and Drug Administration (FDA)-cleared autonomous AI diagnostic system. It has been installed in nine Labcorp patient service centres across Alabama to treat diabetic people.
The system secured approval from the FDA to identify diabetic retinopathy by examining retinal images for indications of the illness without the requirement for a specialist to interpret and analyse the images.
Digital Diagnostics’ co-founder, president and chief operating officer Dr Seth Rainford said: “This strategic relationship with Labcorp to bring LumineticsCore to their patient service centres aligns with their mission to improve health and improve lives.”
The LumineticsCore test combines self-governing AI with a laboratory service centre environment, making it the first-of-its-kind solution.
Labcorp’s current IT infrastructure supports the integration of LumineticsCore without requiring any further technical effort.
Physicians order the eye exam for individuals with diabetes through an electronic medical record system, similar to other tests at Labcorp centres.
Although the diabetic retina exam aims to prevent visual loss and blindness in diabetes patients, it is not a substitute for the eight-point eye exam.
Labcorp Diagnostic’s Southeast Division senior vice-president Lenny Monsour said: “Working with Digital Diagnostics allows us to offer an expanded set of services to our patients while empowering our providers with more ways to serve the health care needs of their local communities.”